GSK Claims R&D Misconduct In China Has Been Eliminated

Law360, New York (July 23, 2013, 3:20 PM EDT) -- GlaxoSmithKline PLC on Tuesday tried to stanch the bleeding in a fast-evolving scandal surrounding its business dealings in China, acknowledging past misdeeds in its research division while claiming to have subsequently scrubbed out all traces of illegitimate behavior.

In a statement, the British drugmaker described in vague terms that a 2011 audit turned up “a number of recommendations” for improved compliance, and that the company took action.

“Where we find that systems or controls need to be strengthened or individual misconduct has occurred, we take the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.